Product Name: Ganirelix
Synonyms: 183552-38-7 (free base);N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylaMino)Methylene]-D-lysyl-L-leucyl-N6-[bis(ethylaMino)Methylene]-L-lysyl-L-prolyl-;Ganirelix acetate salt;N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamide diacetate
CAS: 129311-55-3
MF: C80H113ClN18O13
MW: 1570.31902
EINECS:
Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File: 129311-55-3.mol
Ganirelix Structure
Ganirelix Chemical Properties
storage temp. ?20°C
form lyophilized powder
pka 4.2 (3-pyridinylalanine); 9.8 (tyrosine)
color white
InChIKey GJNXBNATEDXMAK-PFLSVRRQSA-N
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
WGK Germany 3
MSDS Information
Ganirelix Usage And Synthesis
Description Ganirelix acetate was introduced in Germany as prefilled syringes for subcutaneous injections that inhibit premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation. This decapeptide analog of luteinizing hormonereleasing hormone (LH-RH) is the second third-generation LH-RH antagonist to be launched after citrorelix (Asta Medica). This highly bioavailable compound immediately blocks the endogenous release by the pituitary gland of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the hormone that induces ovulation. After discontinuation of the treatment, the pituitary-gonadal function is rapidly recovered due to its short-half life. As a consequence, ganirelix at daily doses of 0.25 mg S.C. efficiently prevented LH surges during clinical trials in infertile women under controlled ovarian hyperstimulation with recombinant FSH before in vitro fertilization or similar reproductive techniques. Unlike first and second-generation gonadotropin-releasing hormone antagonists, ganirelix has minimal histamine-releasing effects thus avoiding the formation of edema of the face and extremities. Ganirelix is very resistant to hydrolysis and, in contrast to the already established cetrorelix, has good water solubility.
Originator Roche Bioscience (US)
Uses Decapeptide LH-RH antagonist. Used in treatment of infertility.
Brand name Orgalutran
China
